HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Abstract Full Text (PDF) Free All Versions of this Article: 99/6/2115    most recent 00427.2005v1 Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (4) Citing Articles via Google Scholar Google Scholar Articles by Buckwalter, J. B. Articles by Clifford, P. S. Search for Related Content PubMed PubMed Citation Articles by Buckwalter, J. B. Articles by Clifford, P. S.

Neuropeptide Y₁ receptor vasoconstriction in exercising canine skeletal muscles

Departments of Anesthesiology and Physiology, Medical College of Wisconsin and Veterans Affairs Medical Center, Milwaukee, Wisconsin

Submitted 15 April 2005 ; accepted in final form 8 August 2005

	ABSTRACT

TOP ABSTRACT METHODS RESULTS DISCUSSION GRANTS ACKNOWLEDGMENTS REFERENCES

 
Existing evidence suggests that neuropeptide Y (NPY) acts as a neurotransmitter in vascular smooth muscle and is coreleased with norepinephrine from sympathetic nerves. We hypothesized that release of NPY stimulates NPY Y₁ receptors in the skeletal muscle vasculature to produce vasoconstriction during dynamic exercise. Eleven mongrel dogs were instrumented chronically with flow probes on the external iliac arteries of both hindlimbs and a catheter in one femoral artery. In resting dogs (n = 4), a 2.5-mg bolus of BIBP-3226 (NPY Y₁ antagonist) infused into the femoral artery increased external iliac conductance by 150 ± 82% (1.80 ± 0.44 to 3.50 ± 0.14 ml·min^–1·mmHg^–1; P < 0.05). A 10-mg bolus of BIBP-3226 infused into the femoral artery in dogs (n = 7) exercising on a treadmill at a moderate intensity (6 miles/h) increased external iliac conductance by 28 ± 6% (6.00 ± 0.49 to 7.64 ± 0.61 ml·min^–1·mmHg^–1; P < 0.05), whereas the solvent vehicle did not (5.74 ± 0.51 to 5.98 ± 0.43 ml·min^–1·mmHg^–1; P > 0.05). During exercise, BIBP-3226 abolished the reduction in conductance produced by infusions of the NPY Y₁ agonist [Leu³¹,Pro³⁴]NPY (–19 ± 3 vs. 0.5 ± 1%). Infusions of BIBP-3226 (n = 7) after -adrenergic receptor antagonism with prazosin and rauwolscine also increased external iliac conductance (6.82 ± 0.43 to 8.22 ± 0.48 ml·min^–1·mmHg^–1; P < 0.05). These data support the hypothesis that NPY Y₁ receptors produce vasoconstriction in exercising skeletal muscle. Furthermore, the NPY Y₁ receptor-mediated tone appears to be independent of -adrenergic receptor-mediated vasoconstriction.

blood flow; sympathetic nervous system; autonomic nervous system

The purpose of this study was to examine the effect of NPY Y₁ receptor antagonism on skeletal muscle vascular tone in conscious dogs during exercise. We hypothesized that NPY Y₁ receptors mediate vasoconstriction in exercising skeletal muscle that is independent of -adrenergic vasoconstriction. We expected NPY Y₁ receptor blockade would interrupt tonic vasoconstriction in exercising skeletal muscle, increasing muscle blood flow and muscle vascular conductance. Furthermore, in the presence of -adrenergic receptor antagonism, we expected NPY Y₁ receptor blockade would result in vasodilatation and NPY Y₁ receptor stimulation would produce vasoconstriction.

	METHODS

TOP ABSTRACT METHODS RESULTS DISCUSSION GRANTS ACKNOWLEDGMENTS REFERENCES

 
The experimental procedures described below were approved by the Institutional Animal Care and Use Committee and conducted in accordance with the American Physiological Society's Guiding Principles in the Care and Use of Animals. Mongrel dogs (n = 11, 18–22 kg) were chosen for their willingness to run on a motorized treadmill with minimal training. The dogs were chronically instrumented in a series of three sterile surgeries. The first surgical procedure placed the carotid arteries in skin tubes on the neck so that they could be cannulated percutaneously to measure arterial blood pressure (27, 29). During the second surgery, the dogs were instrumented with flow probes (4-mm ultrasonic transit-time flow probes, Transonic Systems, Ithaca, NY) around the external iliac arteries to measure skeletal muscle blood flow in each hindlimb independently. The cables were then tunneled under the skin to the back. In the final surgery, a heparinized catheter (0.045 in. OD, 0.015 in. ID, 60 cm long; Data Science International, St. Paul, MN) was implanted in one hindlimb. This catheter was inserted through a side branch into the femoral artery distal to the flow probes and tunneled to the back of the dog. After recovery, this catheter allowed for the infusion of drugs into the arterial vasculature of one hindlimb. For all surgical procedures, anesthesia was induced with thiopental sodium (15–30 mg/kg; Gensia Pharmaceuticals, Irvine, CA). After intubation with a cuffed endotracheal tube, a surgical level of anesthesia was maintained through mechanical ventilation with 1.5% halothane (Halocarbon Laboratories, River Edge, NJ) and 98.5% oxygen. Antibiotics (cefazolin sodium, Apothecon, Princeton, NJ) and analgesic drugs (buprenorphine hydrochloride, 0.3 mg; Reckitt and Coleman, Kingston-upon-Hull, UK) were given postoperatively. To maintain patency, the femoral catheter was flushed daily with saline and filled with a heparin solution (100 IU heparin/ml in 50% dextrose solution). The dogs were given at least 2 days to recover from the final surgery before any experiments were performed. On completion of the experiments, the animals were euthanized (100 mg/kg pentobarbital sodium iv and saturated KCl iv), and the flow probes were retrieved.

All experiments were performed in a laboratory in which the temperature was maintained below 20°C. On the day of the experiment, the dog was brought to the laboratory, and a 20-gauge intravascular catheter (Insyte, Becton Dickinson, Sandy, UT) was inserted retrogradely into the lumen of the carotid artery. The carotid catheter was attached to a solid-state pressure transducer (Ohmeda, Madison, WI), and the flow probes were connected to a transit-time flowmeter (Transonic Systems).

To confirm the existence of tonic NPY Y₁ receptor tone in resting skeletal muscle (16, 23, 28, 32), a selective NPY Y₁ receptor antagonist (BIBP-3226, Bachem, King of Prussia, PA) was infused while the animals rested quietly. This antagonist was chosen for its selectivity for the NPY Y₁ receptor (25) and for its ability to be dissolved in aqueous solution. BIBP-3226 was dissolved in bacteriostatic water at a concentration of 1 mg/ml and administered as a bolus infusion of 2.5 mg. Given the lower external iliac blood flow at rest, this dose was roughly proportional to the dose given during exercise. This proportional dosing results in a similar effective concentration of the antagonist at different magnitudes of external iliac blood flow.

To test the salient hypothesis of this study, that NPY Y₁ receptors mediate vasoconstriction in the arterial vasculature of exercising skeletal muscle, a bolus intra-arterial infusion of BIBP-3226 (10 mg) was given while the dogs (n = 7) exercised at a moderate workload of 6 miles/h (9.7 km/h). Control experiments using the solvent vehicle for BIBP-3226 were performed on a different day. The solvent vehicle control and the BIBP-3226 were given in random order. In separate experiments (n = 7), the effectiveness and selectivity of the BIBP-3226 was determined with intra-arterial infusions of the selective NPY Y₁ receptor agonist [Leu³¹,Pro³⁴]NPY (Bachem) before and after administration of BIBP-3226. The [Leu³¹,Pro³⁴]NPY was dissolved in bacteriostatic water and infused as a bolus at a concentration of 0.1 µg of [Leu³¹,Pro³⁴]NPY per milliliter of external iliac blood flow during steady-state exercise at 6 miles/h (9.7 km/h).

The independence of NPY Y₁ receptor-mediated vasoconstriction from -adrenergic receptor tone was examined with intra-arterial infusions of BIBP-3226 after -adrenergic receptor antagonism (n = 7). Because both ₁- and ₂-adrenergic receptors have been shown to produce tonic vasoconstriction in exercising skeletal muscle (4, 8), both ₁- and ₂-adrenergic receptors were blocked. A combined bolus of 100 µg prazosin (Pfizer, Groton, CT) and 1 mg of rauwolscine (RBI, Natick, MA) was given intra-arterially while the dog ran on the treadmill at 6 miles/h (9.7 km/h). After blood flow stabilized, a 10-mg bolus of BIBP-3226 was given as previously described. To establish the effectiveness and selectivity, intra-arterial infusions of norepinephrine (Abbott Laboratories, North Chicago, IL) and [Leu³¹,Pro³⁴]NPY were given in the presence of prazosin and rauwolscine. These data were also collected while the dog exercised on a motorized treadmill at a moderate workload [6 miles/h (9.7 km/h)]. All of the experiments examining the vasoconstrictor effect of norepinephrine and [Leu³¹,Pro³⁴]NPY in the presence of -adrenergic receptor antagonism occurred on a separate day from those experiments examining the effect of BIBP-3226 after -adrenergic receptor antagonism.

A computer (Apple G3 Power PC) using a Powerlab system (ADInstruments, Castle Hill, Australia) was used to record (at 100 Hz) arterial blood pressure and right and left external iliac blood flow during all experiments. Data were analyzed offline using the MacLab software to calculate mean arterial pressure, heart rate, iliac blood flow, and iliac vascular conductance (blood flow/mean arterial pressure). Vascular conductance was calculated rather than vascular resistance because conductance better reflects vascular tone when the experimental manipulation causes a change primarily in flow and not pressure (19). Baseline measurements were averaged over 30 s before antagonist and agonist infusion. After the infusion of BIBP-3226, all variables were averaged over 1-s intervals (100 consecutive data points), and the highest 1-s average for vascular conductance was chosen as the peak response. In addition, steady-state values representing a 5 s (500 consecutive data points) average were taken 30 s after the end of the BIBP-3226 infusion. After all agonist (norepinephrine and [Leu³¹,Pro³⁴]NPY) infusions, all variables were averaged over 1-s intervals (100 consecutive data points), and the nadir 1-s average for vascular conductance was chosen as the peak response.

An level of P < 0.05 was used to establish statistical significance during all analysis. Statistical analyses of the data were performed with a repeated-measures analysis of variance. Where significant F-ratios were found, a Tukey's post hoc test was performed. All data are expressed as means ± SE.

	RESULTS

TOP ABSTRACT METHODS RESULTS DISCUSSION GRANTS ACKNOWLEDGMENTS REFERENCES

 
At rest (n = 4), intra-arterial infusion of BIBP-3226 produced increases in experimental limb blood flow and conductance. Steady state blood flow increased from 202 ± 55 to 377 ± 31 ml/min (P < 0.05). Vascular conductance increased by 150 ± 82% from 1.80 ± 0.44 to 3.50 ± 0.14 ml·min^–1·mmHg^–1 (P < 0.05).

Figure 1 is an original tracing from one experiment showing the effect of intra-arterial infusion of BIBP-3226. Intra-arterial infusion of BIBP-3226 interrupted tonic NPY Y₁ receptor-mediated vasoconstriction in exercising skeletal muscle, resulting in substantial increases in experimental limb blood flow. In the seven dogs, intra-arterial infusion of selective NPY Y₁ receptor antagonist BIBP-3226 during exercise produced peak increases in experimental limb conductance of 28 ± 6% (P < 0.05) (Fig. 2). This was achieved in the absence of changes in systemic hemodynamics or contralateral limb blood flow (Table 1). Intra-arterial infusion of the solvent vehicle for BIBP-3226 did not produce any significant (P > 0.05) changes in experimental limb vascular conductance (Fig. 2), systemic hemodynamics, or control limb blood flow (Table 1). The dose of BIBP-3226 produced effective blockade of NPY Y₁ receptors as demonstrated by the fact that the selective NPY Y₁ receptor agonist [Leu³¹,Pro³⁴]NPY decreased vascular conductance by 1.17 ± 0.23 (or 19 ± 3%) ml·min^–1·mmHg^–1 and blood flow by 117 ± 24 ml/min under control conditions and by 0.06 ± 0.09 (or 0.5 ± 1%) ml·min^–1·mmHg^–1 and blood flow by 11 ± 10 ml/min after BIBP-3226 (n = 7; P < 0.05).

View larger version (25K): [in this window] [in a new window]   Fig. 1. Original record from an individual dog showing the response to an intra-arterial bolus of BIBP-3226 during steady-state exercise at 6 miles/h. Arrow, beginning of the intra-arterial infusion of the selective neuropeptide Y (NPY) Y1 receptor antagonist into the femoral artery of the experimental limb. The infusion produced a substantial increase in iliac blood flow and conductance in the experimental limb with little or no change in the contralateral limb.

View larger version (16K): [in this window] [in a new window]   Fig. 2. Experimental limb conductance during exercise at 6 miles/h before and after intra-arterial infusion of BIBP-3226 or the solvent vehicle. Values are means ± SE; n = 7 dogs. Experimental limb iliac conductance was significantly (P < 0.05) higher (peak and at 30 s) after intra-arterial infusion of BIBP-3226 compared with baseline. Infusion of BIBP-3226 interrupted tonic NPY Y1 receptor-mediated vasoconstriction in the arterial vasculature of skeletal muscle, resulting in significant (P < 0.05) vasodilation compared with baseline. In contrast, intra-arterial infusion of the solvent vehicle did not alter iliac vascular conductance in the experimental limb.

View larger version (23K): [in this window] [in a new window]   Fig. 3. Experimental limb conductance during exercise at 6 miles/h before and after intra-arterial infusion of BIBP-3226 in the presence of -adrenergic receptor blockade. Values are means ± SE; n = 7 dogs. Experimental limb iliac conductance was significantly (P < 0.05) higher after intra-arterial infusion of the -adrenergic receptor antagonist (rauwolscine + prazosin) compared with baseline. Intra-arterial infusion of BIBP-3226 caused an additional increase (P < 0.05) in iliac vascular conductance in the experimental limb. Infusion of BIBP-3226 interrupted tonic NPY Y1 receptor-mediated vasoconstriction in the arterial vasculature of skeletal muscle that was independent of -adrenergic receptor vasoconstriction.

View larger version (15K): [in this window] [in a new window]   Fig. 4. Percent changes from baseline in iliac conductance resulting from intra-arterial infusion of [Leu31,Pro34]NPY Y (NPY Y1 agonist) or norepinephrine (NE) before (control) and after (-blockade) -adrenergic receptor antagonism with rauwolscine and prazosin. Values are means ± SE; n = 7. Intra-arterial infusion of [Leu31,Pro34]NPY into the experimental limb produced significant (P < 0.05) reductions in iliac vascular conductance in the absence and presence of -adrenergic receptor blockade. The magnitude of constriction produced with [Leu31,Pro34]NPY was not significantly altered (P > 0.05) by -receptor antagonism. In contrast, intra-arterial infusion of norepinephrine produced significant (P < 0.05) reductions in iliac vascular conductance that were abolished by -adrenergic receptor blockade. After -adrenergic receptor blockade, NE did not significantly (P > 0.05) reduce vascular conductance.

	DISCUSSION

TOP ABSTRACT METHODS RESULTS DISCUSSION GRANTS ACKNOWLEDGMENTS REFERENCES

A body of literature exists that indicates -adrenergic receptors tonically restrain blood flow to exercising skeletal muscle even during intense exercise (4, 8, 31). Traditional dogma characterizes sympathetic vasoconstriction as the release of norepinephrine from sympathetic nerve terminals to stimulate -adrenergic receptors on vascular smooth muscle. However, in recent years, evidence has emerged that other neurotransmitters are coreleased along with norepinephrine from sympathetic nerves (15, 17, 23, 34), the best described of these sympathetic cotransmitters being ATP and NPY. Recently, our laboratory provided evidence of a role for purinergic P2X receptors in the regulation of skeletal muscle blood flow at rest and during exercise (6, 10). Furthermore, the fact that stimulation of NPY Y₁ receptors elicits vasoconstriction in exercising muscle suggests that NPY may also have a role in the control of blood flow to exercising skeletal muscle (10). NPY is one of three peptides (along with pancreatic polypeptide and peptide YY) belonging to the polypeptide-fold family of peptides (1). All of these peptides bind G protein-coupled receptors. However, NPY is unique among the three peptides in the fact that it is strictly localized in neurons (1). Postganglionic sympathetic nerves have been shown to contain vesicles containing NPY (20). In contrast to norepinephrine, which is found in both small and large vesicles in sympathetic neurons, NPY is stored only in large dense-cored vesicles (21). The release of these large dense-cored vesicles containing NPY appears to be dependent on high-frequency stimulation (20). Once released, NPY can stimulate a number of different subtypes of NPY receptors. Although different subtypes of Y receptors exist, the Y₁ and Y₂ receptors appear to play the most prominent roles in the cardiovascular system. The Y₁ receptor has been proposed to be primarily situated postjunctionally on vascular smooth muscle, where it mediates vasoconstriction in small vessels. NPY Y₁ receptor stimulation produces vasoconstriction at the arteriolar level but not in larger conduit vessels (34). The Y₂ receptor is mainly prejunctional and inhibits the release of norepinephrine (42). Interestingly, ₂-adrenergic receptors located prejunctionally on the sympathetic nerve terminal have been shown to reciprocate by inhibiting the release of NPY (21).

Although neuropeptide Y is present in the perivascular noradrenergic neurons innervating the vasculature of skeletal muscle (34), and has been shown to produce vasoconstriction in resting skeletal muscle, we believe the present study is the first to demonstrate that NPY Y₁ receptors influence vascular tone in exercising skeletal muscle. Previously, it has been reported that there is a substantial increase in plasma concentration of NPY during dynamic exercise (22, 33). One might speculate that the increase in circulating NPY is likely the result of NPY spillover associated with the large increase in sympathetic nerve activity to exercising skeletal muscle. This seems reasonable considering the data from the present study showing that NPY Y₁ receptors are tonically active during exercise and previous data showing that NPY Y₁ receptor stimulation produces vasoconstriction in exercising skeletal muscle even during intense exercise (10). The demonstration of tonic NPY Y₁ receptor-mediated vasoconstriction in exercising skeletal muscle has important implications for the regulation of blood pressure during exercise. To meet the increase in oxygen demands during exercise, there is a redistribution of cardiac output away from nonexercising tissue toward exercising skeletal muscle. It has long been argued that because a greater proportion of cardiac output is directed toward active skeletal muscle as exercise intensity increases, sympathetic vasoconstriction of active skeletal muscle becomes increasingly important for the regulation of arterial blood pressure (10). This vasoconstriction has previously been shown to be mediated by -adrenergic receptors (4, 8, 13, 31). Along with -adrenergic receptors, it now appears that NPY Y₁ receptors may play a role in the regulation of systemic arterial pressure during exercise.

The present study also confirms the existence of tonic NPY Y₁-mediated vasoconstriction in resting skeletal muscle (16, 23, 28, 32). Recognizing that the data come from different groups of animals, the present results permit a comparison of the magnitude of tonic Y₁ receptor vasoconstriction during rest and exercise. Interruption of tonic Y₁-mediated vasoconstriction resulted in a 150% increase in vascular conductance at rest compared with a 28% increase during moderate-intensity exercise. These data do not allow any conclusion regarding the intensity-related effects, but they do show greater NPY Y₁ receptor-mediated vasoconstriction at rest compared with exercise. This pattern is similar to that observed for -adrenergic and purinergic receptors in the skeletal muscle vasculature (4, 10). Previous work from our laboratory (3, 4, 39) and others (18, 35, 36, 40) demonstrates that sympathetic vasoconstriction is attenuated in exercising skeletal muscle. In addition, our laboratory recently reported that Y₁ receptor responsiveness is attenuated during exercise compared with rest and that this attenuation is related to exercise intensity (7). Taken together, it seems reasonable to predict that compared with rest tonic Y₁ receptor-mediated vasoconstriction is attenuated during exercise to a greater degree as exercise intensifies, but further studies will be needed to specifically test this hypothesis.

Pernow and colleagues (32) showed in resting canine skeletal muscle that NPY mediates vasoconstriction that is resistant to -adrenergic receptor blockade. The present study extends those findings to exercising skeletal muscle. Furthermore, the stimulation of NPY Y₁ receptors produces the same vasoconstrictor effect in the presence of tonic -adrenergic vasoconstriction as it does in the absence of -adrenergic tone. Although it appears that NPY Y₁ receptors can mediate vasoconstriction independently of -adrenergic receptors, these data do not exclude an interaction between -adrenergic receptors and NPY. Indeed a number of studies have shown that the effects of -adrenergic stimulation are potentiated in the presence of NPY (24, 38, 41). Interestingly, NPY can potentiate the effect of -adrenergic stimulation at doses that have negligible vasoconstrictor effects by themselves (38, 41). This phenomenon appears to be restricted to blood vessels predominantly populated by ₁-adrenergic receptors (41). It is possible that increases in circulating levels of NPY during exercise may be important in the regulation of blood pressure during exercising by potentiating -adrenergic receptor-mediated vasoconstriction.

The results from the present study reveal that NPY Y₁ receptor antagonism in exercising skeletal muscle produces an increase in blood flow and conductance. In addition, there appears to be NPY Y₁ receptor-mediated vasoconstriction that is independent of -adrenergic receptor tone. The demonstration that the NPY Y₁ receptor regulates skeletal muscle vascular tone during exercise suggests that it may be involved in the regulation of systemic arterial pressure during exercise.

	GRANTS

TOP ABSTRACT METHODS RESULTS DISCUSSION GRANTS ACKNOWLEDGMENTS REFERENCES

 
This project was supported by the Medical Research Service of the Department of Veterans Affairs and the National Heart, Lung, and Blood Institute.

	ACKNOWLEDGMENTS

TOP ABSTRACT METHODS RESULTS DISCUSSION GRANTS ACKNOWLEDGMENTS REFERENCES

 
The authors acknowledge the valuable technical assistance of Paul Kovac and Jessica Taylor.

	FOOTNOTES

 

Address for reprint requests and other correspondence: J. Buckwalter, Anesthesia Research 151, VA Medical Center, 5000 W. National Ave., Milwaukee, WI 53295 (e-mail: jbuckwal{at}mcw.edu)

The costs of publication of this article were defrayed in part by the payment of page charges. The article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

	REFERENCES

TOP ABSTRACT METHODS RESULTS DISCUSSION GRANTS ACKNOWLEDGMENTS REFERENCES

 

1. Berglund MM, Hipskind PA, and Gehlert DR. Recent developments in our understanding of the physiological role of PP-fold peptide receptor subtypes. Exp Biol Med (Maywood) 228: 217–244, 2003.[Abstract/Free Full Text]
2. Buckwalter JB and Clifford PS. The paradox of sympathetic vasoconstriction in exercising skeletal muscle. Exerc Sport Sci Rev 29: 159–163, 2001.[CrossRef][Medline]
3. Buckwalter JB, Naik JS, Valic Z, and Clifford PS. Exercise attenuates -adrenergic receptor responsiveness in skeletal muscle vasculature. J Appl Physiol 90: 172–178, 2001.[Abstract/Free Full Text]
4. Buckwalter JB and Clifford PS. -Adrenergic vasoconstriction in active skeletal muscles during dynamic exercise. Am J Physiol Heart Circ Physiol 277: H33–H39, 1999.[Abstract/Free Full Text]
5. Buckwalter JB and Clifford PS. Autonomic influence on skeletal muscle blood flow at the onset of dynamic exercise. Am J Physiol Heart Circ Physiol 277: H1872–H1877, 1999.[Abstract/Free Full Text]
6. Buckwalter JB, Hamann JJ, and Clifford PS. Vasoconstriction in active skeletal muscles: a potential role for P2X purinergic receptors? J Appl Physiol 95: 953–959, 2003.[Abstract/Free Full Text]
7. Buckwalter JB, Hamann JJ, Kluess HL, and Clifford PS. Vasoconstriction in active skeletal muscles: a potential role for neuropeptide Y? Am J Physiol Heart Circ Physiol 287: H144–H149, 2004.[Abstract/Free Full Text]
8. Buckwalter JB, Mueller PJ, and Clifford PS. Sympathetic vasoconstriction in active skeletal muscles during dynamic exercise. J Appl Physiol 83: 1575–1580, 1997.[Abstract/Free Full Text]
9. Buckwalter JB, Ruble SB, Mueller PJ, and Clifford PS. Skeletal muscle vasodilation at the onset of exercise. J Appl Physiol 85: 1649–1654, 1998.[Abstract/Free Full Text]
10. Buckwalter JB, Taylor JC, Hamann JJ, and Clifford PS. Do P2X purinergic receptors regulate skeletal muscle blood flow during exercise? Am J Physiol Heart Circ Physiol 286: H633–H639, 2004.[Abstract/Free Full Text]
11. DiCarlo SE, Chen CY, and Collins HL. Onset of exercise increases lumbar sympathetic nerve activity in rats. Med Sci Sports Exerc 28: 677–684, 1996.
12. Hajduczok G, Hade JS, Mark AL, Williams JL, and Felder RB. Central command increases sympathetic nerve activity during spontaneous locomotion in cats. Circ Res 69: 66–75, 1991.[Abstract/Free Full Text]
13. Hamann JJ, Buckwalter JB, Valic Z, and Clifford PS. Sympathetic restraint of muscle blood flow at the onset of dynamic exercise. J Appl Physiol 92: 2452–2456, 2002.[Abstract/Free Full Text]
14. Hill JM, Adreani CM, and Kaufman MP. Muscle reflex stimulates sympathetic postganglionic efferents innervating triceps surae muscles of cats. Am J Physiol Heart Circ Physiol 271: H38–H43, 1996.[Abstract/Free Full Text]
15. Hopwood AM and Burnstock G. ATP mediates coronary vasoconstriction via P_2X-purinoceptors and coronary vasodilation via P_2Y-purinoceptors in the isolated perfused rat heart. Eur J Pharmacol 136: 49–54, 1987.[CrossRef][Web of Science][Medline]
16. Hu Y and Dunbar JC. Regional vascular cardiac responses to systemic neuropeptide-Y in normal and diabetic rats. Peptides 18: 809–815, 1997.[CrossRef][Web of Science][Medline]
17. Kennedy C, Saville VL, and Burnstock G. The contributions of noradrenaline and ATP to the responses of the rabbit central ear artery to sympathetic nerve stimulation depend on the parameters of stimulation. Eur J Pharmacol 122: 291–300, 1986.[CrossRef][Web of Science][Medline]
18. Klabunde RE. Attenuation of reactive and active hyperemia by sympathetic stimulation in dog gracilis muscle. Am J Physiol Heart Circ Physiol 251: H1183–H1187, 1986.[Abstract/Free Full Text]
19. Lautt WW. Resistance or conductance for expression of arterial vascular tone. Microvasc Res 37: 230–236, 1989.[CrossRef][Web of Science][Medline]
20. Lundberg JM, Franco-Cereceda A, Lou YP, Modin A, and Pernow J. Differential release of classical transmitters and peptides. Adv Second Messenger Phosphoprotein Res 29: 223–234, 1994.[Web of Science][Medline]
21. Lundberg JM, Franco-Cereceda A, Lacroix JS, and Pernow J. Neuropeptide Y and sympathetic neurotransmission. Ann NY Acad Sci 611: 166–174, 1990.[Web of Science][Medline]
22. Lundberg JM, Martinsson A, Mensen A, Theodorsson-Norheim E, Svedenhag J, Ekblom B, and Hjemdahl P. Co-release of neuropeptide Y and catecholamines during physical exercise in man. Biochem Biophys Res Commun 133: 30–36, 1985.[CrossRef][Web of Science][Medline]
23. Lundberg JM and Modin A. Inhibition of sympathetic vasoconstriction in pigs in vivo by neuropeptide Y-Y1 receptor antagonist BIBP 3226. Br J Pharmacol 116: 2971–2982, 1995.[Web of Science][Medline]
24. Mabe Y, Tatemoto K, and Huidobro-Toro JP. Neuropeptide Y induced pressor responses: activation of a non-adrenergic mechanism, potentiation by reserpine and blockade by nifedipine. Eur J Pharmacol 116: 33–39, 1985.[CrossRef][Web of Science][Medline]
25. Malmstrom RE, Hokfelt T, Bjorkman JA, Nihlen C, Bystrom M, Ekstrand AJ, and Lundberg JM. Characterization and molecular cloning of vascular neuropeptide Y receptor subtypes in pig and dog. Regul Pept 75–76: 55–70, 1998.
26. Marshall RJ, Schirger A, and Shepherd JT. Blood pressure during supine exercise idiopathic orthostatic hypotension. Circulation 24: 76–81, 1961.[Abstract/Free Full Text]
27. Meier MA and Long DM. Carotid artery loop for repeated catheterization of the left verntricle in dogs. Surgery 70: 797–799, 1971.[Web of Science][Medline]
28. Nilsson T, Hrafnkelsdottier T, Edvinsson L, Jern S, Erlinge D, and Wall U. Forearm blood flow responses to neuropeptide Y, noradrenaline and adenosine 5-triphosphate in hypertensive and normotensive subjects. Blood Press 9: 126–131, 2000.[CrossRef][Web of Science][Medline]
29. O'Brien DJ, Chapman WH, Rudd FV, and McRoberts JW. Carotid artery loop method of blood pressure measurement in the dog. J Appl Physiol 30: 161–163, 1971.[Free Full Text]
30. O'Hagan KP, Bell LB, Mittelstadt SW, and Clifford PS. Effect of dynamic exercise on renal sympathetic nerve activity in conscious rabbits. J Appl Physiol 74: 2099–2104, 1993.[Abstract/Free Full Text]
31. O'Leary DS, Robinson ED, and Butler JL. Is active skeletal muscle functionally vasoconstricted during dynamic exercise in conscious dogs? Am J Physiol Regul Integr Comp Physiol 272: R386–R391, 1997.[Abstract/Free Full Text]
32. Pernow J, Kahan T, Hjemdahl P, and Lundberg JM. Possible involvement of neuropeptide Y in sympathetic vascular control of canine skeletal muscle. Acta Physiol Scand 132: 43–50, 1988.[Web of Science][Medline]
33. Pernow J, Lundberg JM, Kaijser L, Hjemdahl P, Theodorsson-Norheim E, Martinsson A, and Pernow B. Plasma neuropeptide Y-like immunoreactiviity and catecholamines during various degrees of sympathetic activation in man. Clin Physiol 6: 561–578, 1986.[Web of Science][Medline]
34. Pernow J, Ohlen A, Hokfelt T, Nilsson O, and Lundberg JM. Neuropeptide Y: presence in perivascular noradrenergic neurons and vasoconstrictor effects on skeletal muscle blood vessels in experimental animals and man. Regul Pept 19: 313–324, 1987.[CrossRef][Web of Science][Medline]
35. Remensnyder JP, Mitchell JH, and Sarnoff SJ. Functional sympatholysis during muscular activity. Circ Res 11: 370–380, 1962.[Abstract/Free Full Text]
36. Rosenmeier JB, Dinenno FA, Fritzlar SJ, and Joyner MJ. ₁ and ₂ adrenergic vasoconstriction is blunted in contracting human muscle. J Physiol 547: 971–976, 2003.[Abstract/Free Full Text]
37. Rowell LB. Human Cardiovascular Control. New York: Oxford Universtiy Press, 1993.
38. Schuerch LV, Linder LM, Grouzmann E, and Haefeli WE. Human neuropeptide Y potentiates ₁ adrenergic blood pressure responses in vivo. Am J Physiol Heart Circ Physiol 275: H760–H766, 1998.[Abstract/Free Full Text]
39. Ruble SB, Valic Z, Buckwalter JB, Tschakovsky ME, and Clifford PS. Attenuated vascular responsiveness to norepinephrine release during dynamic exercise in dogs. J Physiol 541: 637–644, 2002.[Abstract/Free Full Text]
40. Tschakovsky ME, Sujirattanawimol K, Ruble SB, Valic Z, and Joyner MJ. Is sympathetic neural vasoconstriction blunted in the vascular bed of exercising human muscle? J Physiol 541: 623–635, 2002.[Abstract/Free Full Text]
41. Wahlestedt C, Edvinsson L, Ekblad E, and Hakanson R. Neuropeptide Y potentiates noradrenaline-evoked vasoconstriction: mode of action. J Pharmacol Exp Ther 234: 735–741, 1985.[Abstract/Free Full Text]
42. Wahlestedt C, Yanaihara N, and Hakanson R. Evidence for different pre- and post-junctional receptors for neuropeptide Y and related peptides. Regul Pept 13: 307–318, 1986.[CrossRef][Web of Science][Medline]

This article has been cited by other articles:

				G. J. Hodges, D. N. Jackson, L. Mattar, J. M. Johnson, and J. K. Shoemaker Neuropeptide Y and neurovascular control in skeletal muscle and skin Am J Physiol Regulatory Integrative Comp Physiol, September 1, 2009; 297(3): R546 - R555. [Abstract] [Full Text] [PDF]

				J. C. Taylor, H. T. Yang, M. H. Laughlin, and R. L. Terjung {alpha}-Adrenergic and neuropeptide Y Y1 receptor control of collateral circuit conductance: influence of exercise training J. Physiol., December 15, 2008; 586(24): 5983 - 5998. [Abstract] [Full Text] [PDF]

				J. C. Taylor, Z. Li, H. T. Yang, M. H. Laughlin, and R. L. Terjung {alpha}-Adrenergic inhibition increases collateral circuit conductance in rats following acute occlusion of the femoral artery J. Physiol., March 15, 2008; 586(6): 1649 - 1667. [Abstract] [Full Text] [PDF]

This Article Abstract Full Text (PDF) Free All Versions of this Article: 99/6/2115    most recent 00427.2005v1 Submit a response Alert me when this article is cited Alert me when eLetters are posted Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (4) Citing Articles via Google Scholar Google Scholar Articles by Buckwalter, J. B. Articles by Clifford, P. S. Search for Related Content PubMed PubMed Citation Articles by Buckwalter, J. B. Articles by Clifford, P. S.